Carregant...
IT-16 COMBINATION TREATMENT WITH DELTA24-RGD AND TEMOZOLOMIDE IMPROVES SURVIVAL AND AFFECTS INTRATUMORAL IMMUNE CELL SUBSETS IN A MURINE MALIGNANT GLIOMA MODEL
INTRODUCTION: The oncolytic adenovirus Delta24-RGD specifically lyses tumor cells and is currently tested in clinical phase I/II trials for recurrent glioma. We recently showed that the efficacy of Delta24-RGD is mainly dependent on an induced anti-tumor immune response. As known, TMZ has pronounced...
Guardat en:
| Autors principals: | , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Oxford University Press
2014
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4218232/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou258.14 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|